Literature DB >> 32997292

Molecular Regulatory Mechanism and Toxicology of Neurodegenerative Processes in MPTP/Probenecid-Induced Progressive Parkinson's Disease Mice Model Revealed by Transcriptome.

Weiwei Yang1, Wenwen Hao1, Zhuo Meng1, Shiyan Ding1, Xiaodi Li1, Tao Zhang1, Weixiao Huang1, Lian Xu2, Yu Zhang1, Jian Yang3, Xiaosong Gu4,5.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disease caused by a variety of unclear complex pathogenic factors. The 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine/probenecid (MPTP/p)-induced progressive PD mice is a well-recognized classic model for studying PD, but the molecular toxicology of this model is still unclear. Here, for the first time, we report gradual neurodegenerative processes in MPTP/p-induced progressive PD mice model using RNA-seq. Transcriptional responses are orchestrated to regulate the expression of many genes in substantia nigra, such as Ntf3, Pitx3, Th, and Drd2, leading to the degeneration of dopaminergic neurons at last. We proposed that the established model could be divided into three phases based on their molecular toxicological features: "the stress response phase" which maintained the microenvironment homeostasis, "the pre-neurodegenerative phase" which demonstrated observed MPTP/p cytotoxicity and gradual degeneration of dopaminergic neurons, and "the neurodegenerative phase" which reflected distinct damage and dopaminergic neuron apoptotic process. Glia cells exhibited a certain protective effect on dopaminergic neurons in 3rd and 6th MPTP/p-induced cytotoxicity. But in 10th MPTP/p injection, glia cells play a promoting role in PD and tissue damages caused by oxidative stress. This study also indicated that the substantia nigra of PD mice showed unique patterns of changes at each stage. Moreover, neurotrophic signaling pathway, ECM-receptor interaction, oxidative phosphorylation, apoptosis and necroptosis were enriched at 3rd and 6th MPTP/p injection, which might be associated with the PD progress. This study provided an extensive data set of molecular toxicology for elucidating of PD progression and offered comprehensive theoretical knowledge for the development of new therapy.

Entities:  

Keywords:  MPTP/p; Molecular toxicology; Neurodegeneration; Parkinson’s disease; RNA sequencing

Year:  2020        PMID: 32997292      PMCID: PMC7843579          DOI: 10.1007/s12035-020-02128-5

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  41 in total

1.  Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.

Authors:  Jeffrey H Kordower; C Warren Olanow; Hemraj B Dodiya; Yaping Chu; Thomas G Beach; Charles H Adler; Glenda M Halliday; Raymond T Bartus
Journal:  Brain       Date:  2013-08       Impact factor: 13.501

2.  The current and projected economic burden of Parkinson's disease in the United States.

Authors:  Stacey L Kowal; Timothy M Dall; Ritashree Chakrabarti; Michael V Storm; Anjali Jain
Journal:  Mov Disord       Date:  2013-02-21       Impact factor: 10.338

3.  Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.

Authors:  Katia Noyes; Hangsheng Liu; Yue Li; Robert Holloway; Andrew W Dick
Journal:  Mov Disord       Date:  2006-03       Impact factor: 10.338

4.  Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease.

Authors:  Sangjune Kim; Seung-Hwan Kwon; Tae-In Kam; Nikhil Panicker; Senthilkumar S Karuppagounder; Saebom Lee; Jun Hee Lee; Wonjoong Richard Kim; Minjee Kook; Catherine A Foss; Chentian Shen; Hojae Lee; Subhash Kulkarni; Pankaj J Pasricha; Gabsang Lee; Martin G Pomper; Valina L Dawson; Ted M Dawson; Han Seok Ko
Journal:  Neuron       Date:  2019-06-26       Impact factor: 17.173

Review 5.  Cell replacement therapy is the remedial solution for treating Parkinson's disease.

Authors:  Venkatesan Dhivya; Vellingiri Balachandar
Journal:  Stem Cell Investig       Date:  2017-06-30

Review 6.  Stages in the development of Parkinson's disease-related pathology.

Authors:  Heiko Braak; Estifanos Ghebremedhin; Udo Rüb; Hansjürgen Bratzke; Kelly Del Tredici
Journal:  Cell Tissue Res       Date:  2004-08-24       Impact factor: 5.249

7.  Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model.

Authors:  Tetsuhiro Kikuchi; Asuka Morizane; Daisuke Doi; Hiroaki Magotani; Hirotaka Onoe; Takuya Hayashi; Hiroshi Mizuma; Sayuki Takara; Ryosuke Takahashi; Haruhisa Inoue; Satoshi Morita; Michio Yamamoto; Keisuke Okita; Masato Nakagawa; Malin Parmar; Jun Takahashi
Journal:  Nature       Date:  2017-08-30       Impact factor: 49.962

Review 8.  Deep Brain Stimulation in Movement Disorders: From Experimental Surgery to Evidence-Based Therapy.

Authors:  Paul Krack; Jens Volkmann; Gerd Tinkhauser; Günther Deuschl
Journal:  Mov Disord       Date:  2019-10-03       Impact factor: 10.338

Review 9.  Parkinson's disease: animal models and dopaminergic cell vulnerability.

Authors:  Javier Blesa; Serge Przedborski
Journal:  Front Neuroanat       Date:  2014-12-15       Impact factor: 3.856

Review 10.  Parkinson's disease: a dual-hit hypothesis.

Authors:  C H Hawkes; K Del Tredici; H Braak
Journal:  Neuropathol Appl Neurobiol       Date:  2007-10-24       Impact factor: 8.090

View more
  3 in total

1.  Klotho Upregulation via PPARγ Contributes to the Induction of Brain Ischemic Tolerance by Cerebral Ischemic Preconditioning in Rats.

Authors:  Ling-Yan Zhang; Xi-Yun Liu; A-Chou Su; Yu-Yan Hu; Jing-Ge Zhang; Xiao-Hui Xian; Wen-Bin Li; Min Zhang
Journal:  Cell Mol Neurobiol       Date:  2022-07-28       Impact factor: 4.231

Review 2.  Neonatal 6-hydroxydopamine lesioning of rats and dopaminergic neurotoxicity: proposed animal model of Parkinson's disease.

Authors:  Richard M Kostrzewa
Journal:  J Neural Transm (Vienna)       Date:  2022-03-12       Impact factor: 3.850

3.  Effect of Different MPTP Administration Intervals on Mouse Models of Parkinson's Disease.

Authors:  Yuanyuan Ma; Qiongwen Rong
Journal:  Contrast Media Mol Imaging       Date:  2022-03-02       Impact factor: 3.161

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.